Compare Nuwellis Inc (NUWE) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Invesco NASDAQ 100 ETF — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Invesco NASDAQ 100 ETF trades at $309.31 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 51545.5× Nuwellis Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| NUWE | QQQM | |
|---|---|---|
Market Cap | $2.20M | $113.40B |
Volume | 121,544 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $146.65 | $312.76 |
52-Week Low | $0.68 | $229.87 |
Typical Hold Time | 26 Days | 54 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
QQQM (Invesco NASDAQ 100 ETF) trades at $309.27, down 0.88% on the day, with a bullish technical signal from moving averages. The ETF tracks the NASDAQ-100 index with a low 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026. Technical indicators show support at $305 and resistance at $311, with neutral oscillator readings suggesting balanced momentum.
The outlook remains positive given the NASDAQ-100's growth exposure and cost efficiency versus QQQ. Risks include market concentration in technology stocks and potential volatility from macroeconomic factors. Institutional accumulation and favorable expense structure support long-term positioning, though investors should monitor index composition changes and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
